Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions

被引:4
作者
Massimino, Michele [1 ,2 ]
Stella, Stefania [1 ,2 ]
Micale, Giovanni [1 ]
Motta, Lucia [2 ,3 ]
Pavone, Giuliana [2 ,3 ]
Broggi, Giuseppe [4 ]
Piombino, Eliana [5 ]
Magro, Gaetano [4 ]
Parra, Hector Jose Soto [3 ]
Manzella, Livia [1 ,2 ]
Vigneri, Paolo [1 ,2 ,3 ]
机构
[1] Univ Catania, Dept Clin & Expt Med, Catania, Italy
[2] AOU Policlin G Rodol S Marco, Ctr Expt Oncol & Hematol, Catania, Italy
[3] AOU G Rodol S Marco, Med Oncol, Catania, Italy
[4] Univ Catania, Dept Med Surg Sci & Adv Technol GF Ingrassia, Anat Pathol, Catania, Italy
[5] Mediterranean Inst Oncol, Dept Expt Oncol, Pathol Unit, Viagrande, Italy
关键词
Melanoma; survival; mutational landscape; next-generation sequencing; VUS; PPI; DRIVER MUTATIONS; CANCER; SERVER; BENCH;
D O I
10.21873/cgp.20325
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Malignant melanoma is a skin cancer originating from the oncogenic transformation of melanocytes located in the epidermal layers. Usually, the patient's prognosis depends on timing of disease detection and molecular and genetic profiling, which may all significantly influence mortality rates. Genetic analyses often detect somatic BRAF, NRAS and cKIT mutations, germline substitutions in CDKN2A, and alterations of the PI3K-AKTPTEN pathway. A peculiar molecular future of melanoma is its high immunogenicity, making this tumor targetable by programmed cell death protein 1-specific antibodies. Materials and Methods: Ten formalin-fixed paraffin embedded samples derived from melanoma patients were subjected to next-generation sequencing (NGS) analysis using the FDA approved FoundationOne CDxTM test. The molecular features of each case were then analyzed employing several in silico prediction tools. Results: We analyzed the mutational landscape of patients with metastatic or relapsed cutaneous melanoma to define enriched pathways and protein-protein interactions. The analysis showed that both known genetic alterations and variants of unknown significance rely on redundant signaling converging on similar gene ontology biological processes. Complex informatics analyses of NGSbased genetic results identified pivotal signaling pathways that could provide additional targets for cancer treatment. Conclusion: Our data suggest an additional role for NGS in melanoma, as analysis of comprehensive genetic findings using innovative informatic tools may lengthen the list of druggable molecular targets that impact patient outcome.
引用
收藏
页码:350 / 361
页数:12
相关论文
共 36 条
  • [1] A method and server for predicting damaging missense mutations
    Adzhubei, Ivan A.
    Schmidt, Steffen
    Peshkin, Leonid
    Ramensky, Vasily E.
    Gerasimova, Anna
    Bork, Peer
    Kondrashov, Alexey S.
    Sunyaev, Shamil R.
    [J]. NATURE METHODS, 2010, 7 (04) : 248 - 249
  • [2] Genomic Classification of Cutaneous Melanoma
    Akbani, Rehan
    Akdemir, Kadir C.
    Aksoy, B. Arman
    Albert, Monique
    Ally, Adrian
    Amin, Samirkumar B.
    Arachchi, Harindra
    Arora, Arshi
    Auman, J. Todd
    Ayala, Brenda
    Baboud, Julien
    Balasundaram, Miruna
    Balu, Saianand
    Barnabas, Nandita
    Bartlett, John
    Bartlett, Pam
    Bastian, Boris C.
    Baylin, Stephen B.
    Behera, Madhusmita
    Belyaev, Dmitry
    Benz, Christopher
    Bernard, Brady
    Beroukhim, Rameen
    Bir, Natalie
    Black, Aaron D.
    Bodenheimer, Tom
    Boice, Lori
    Boland, Genevieve M.
    Bono, Riccardo
    Bootwalla, Moiz S.
    Bosenberg, Marcus
    Bowen, Jay
    Bowlby, Reanne
    Bristow, Christopher A.
    Brockway-Lunardi, Laura
    Brooks, Denise
    Brzezinski, Jakub
    Bshara, Wiam
    Buda, Elizabeth
    Burns, William R.
    Butterfield, Yaron S. N.
    Button, Michael
    Calderone, Tiffany
    Cappellini, Giancarlo Antonini
    Carter, Candace
    Carter, Scott L.
    Cherney, Lynn
    Cherniack, Andrew D.
    Chevalier, Aaron
    Chin, Lynda
    [J]. CELL, 2015, 161 (07) : 1681 - 1696
  • [3] TERT promoter mutation subtypes and survival in stage I and II melanoma patients
    Andres-Lencina, Juan J.
    Rachakonda, Sivaramakrishna
    Garcia-Casado, Zaida
    Srinivas, Nalini
    Skorokhod, Alexander
    Requena, Celia
    Soriano, Virtudes
    Kumar, Rajiv
    Nagore, Eduardo
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (05) : 1027 - 1036
  • [4] Targeting BRAF for patients with melanoma
    Arkenau, H-T
    Kefford, R.
    Long, G. V.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 104 (03) : 392 - 398
  • [5] Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
    Babacan, Nalan Akgul
    Eroglu, Zeynep
    [J]. CURRENT ONCOLOGY REPORTS, 2020, 22 (04)
  • [6] Melanoma genome sequencing reveals frequent PREX2 mutations
    Berger, Michael F.
    Hodis, Eran
    Heffernan, Timothy P.
    Deribe, Yonathan Lissanu
    Lawrence, Michael S.
    Protopopov, Alexei
    Ivanova, Elena
    Watson, Ian R.
    Nickerson, Elizabeth
    Ghosh, Papia
    Zhang, Hailei
    Zeid, Rhamy
    Ren, Xiaojia
    Cibulskis, Kristian
    Sivachenko, Andrey Y.
    Wagle, Nikhil
    Sucker, Antje
    Sougnez, Carrie
    Onofrio, Robert
    Ambrogio, Lauren
    Auclair, Daniel
    Fennell, Timothy
    Carter, Scott L.
    Drier, Yotam
    Stojanov, Petar
    Singer, Meredith A.
    Voet, Douglas
    Jing, Rui
    Saksena, Gordon
    Barretina, Jordi
    Ramos, Alex H.
    Pugh, Trevor J.
    Stransky, Nicolas
    Parkin, Melissa
    Winckler, Wendy
    Mahan, Scott
    Ardlie, Kristin
    Baldwin, Jennifer
    Wargo, Jennifer
    Schadendorf, Dirk
    Meyerson, Matthew
    Gabriel, Stacey B.
    Golub, Todd R.
    Wagner, Stephan N.
    Lander, Eric S.
    Getz, Gad
    Chin, Lynda
    Garraway, Levi A.
    [J]. NATURE, 2012, 485 (7399) : 502 - 506
  • [7] Melanoma: From Melanocyte to Genetic Alterations and Clinical Options
    Bertolotto, Corine
    [J]. SCIENTIFICA, 2013, 2013
  • [8] EGFR in melanoma: clinical significance and potential therapeutic target
    Boone, Barbara
    Jacobs, Koen
    Ferdinande, Liesbeth
    Taildeman, Jasmien
    Lambert, Jo
    Peeters, Marc
    Bracke, Marc
    Pauwels, Patrick
    Brochez, Lieve
    [J]. JOURNAL OF CUTANEOUS PATHOLOGY, 2011, 38 (06) : 492 - 502
  • [9] Cachia AR, 2000, CLIN CANCER RES, V6, P3511
  • [10] Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study
    Casula, Milena
    Paliogiannis, Panagiotis
    Ayala, Fabrizio
    De Giorgi, Vincenzo
    Stanganelli, Ignazio
    Mandala, Mario
    Colombino, Maria
    Manca, Antonella
    Sini, Maria Cristina
    Caraco, Corrado
    Ascierto, Paolo Antonio
    Satta, Rosanna Rita
    Dedola, Maria Filomena
    Denti, Salvatore
    Fedeli, Maria Antonietta
    Montesu, Maria Antonietta
    Profili, Stefano
    Scotto, Tiziana
    Sini, Germana
    Tanda, Francesco
    Lissia, Amelia
    Cossu, Antonio
    Palmieri, Giuseppe
    Ghiorzo, Paola
    Queirolo, Paola
    Quaglino, Pietro
    Botti, Gerardo
    Sileni, Vanna Chiarion
    Di Giacomo, Anna Maria
    [J]. BMC CANCER, 2019, 19 (01)